A cost-utility analysis of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction
نویسندگان
چکیده
منابع مشابه
Phosphodiesterase type 5 inhibitors for erectile dysfunction.
The cyclic nucleotide signalling pathway mediates the smooth-muscle relaxing effects of nitric oxide necessary for normal erectile function. Down-regulation of this pathway is central to the pathophysiology of many forms of erectile dysfunction (ED), which is often associated with other chronic diseases (e.g. hypertension, type 2 diabetes mellitus) and treatments (e.g. certain drugs, radical pr...
متن کاملUpdate on the Safety of Phosphodiesterase Type 5 Inhibitors for the Treatment of Erectile Dysfunction.
INTRODUCTION Phosphodiesterase type 5 inhibitors (PDE5Is) have demonstrated efficacy in the treatment of erectile dysfunction (ED). Although historically found to have limited drug-related adverse events, emerging data have suggested that PDE5Is might be associated with melanoma or recurrence of prostate cancer after radical prostatectomy. AIM To summarize the literature on the safety of PDE5...
متن کاملPhosphodiesterase-5 (PDE5) Inhibitors In the Management of Erectile Dysfunction.
INTRODUCTION Erectile dysfunction (ED) is the persistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance.1 According to data from the Massachusetts Male Aging Study, up to 52% of men between the ages of 40 and 70 are affected by ED.2 Based on findings from the 2001–2002 National Health and Nutrition Examination Survey (NHANES), it is estimated that 18...
متن کاملPhosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction.
IMPORTANCE TO THE FIELD Since sildenafil was introduced 10 years ago, highly selective phosphodiesterase type 5 inhibitors (PDE5i) have changed the medical management of erectile dysfunction (ED). A significant body of research has been devoted to the use of this class of medication for the treatment of ED and has advanced our understanding of erectile physiology. Recently, investigators have n...
متن کاملToward a new ‘EPOCH’: optimising treatment outcomes with phosphodiesterase type 5 inhibitors for erectile dysfunction
Despite the marked adverse impacts of erectile dysfunction (ED) on quality of life and well-being, many patients (and/or their partners) do not seek medical attention for this problem, do not receive treatment or discontinue such treatment even when it has effectively restored erectile responses to sexual stimulation. Phosphodiesterase type 5 (PDE5) inhibitors are considered first-line therapie...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The European Journal of Health Economics
سال: 2019
ISSN: 1618-7598,1618-7601
DOI: 10.1007/s10198-019-01112-8